Sandu Pharmaceuticals Reports Zero Fund Deviation for Q Ended 30th Sep'26
Sandu Pharmaceuticals Ltd · Others (Uncategorized) · 15 Nov 2026, 12:35 am
Sandu Pharmaceuticals Reports Zero Fund Deviation for Q Ended 30th Sep'26 Sandu Pharmaceuticals reported nil deviation or variation in preferential issue fund utilization for the quarter ended 30th Sep'26 across three tranches. Tranche 1 (₹2,63,79,653 raised on 31st Mar'21) and Tranche 2 (₹1,38,05,408 raised on 28th Feb'22) stand 100% utilized toward plant revamping, marketing infrastructure, civil works, and working capital. From Tranche 3 (₹1,31,94,934 raised on 14th Jul'22), ₹66,45,748.19 has been utilized, while the remaining unutilized capital is parked in a fixed deposit with Bank of Baroda via an escrow account.
Original exchange filing (PDF)
More announcements from Sandu Pharmaceuticals Ltd
- Results for Q and half year ended 30th sept 2026 · 15 Nov 2026
- Outcome of the Board Meeting dated 14th November 2026 · 15 Nov 2026
- Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve Approval of Unaudited .... · 14 Nov 2026
- Intimation about change in name of Director from Dr Neeti Madan Kapre to Dr Neeti Gupta · 09 Oct 2026
- Intimation to the holders of Physical Securities to furnish PAN and KYC details · 30 Sept 2026
- 1. Redesignation of shri Balram Viswanathan (DIN :10245195)as Chairman and Managing Director of the company. 2.Appointment of Dr Smt Neeti Kapre (DIN:06801264)as Non Executive Independent Director · 12 Sept 2026
- Appointment of M/s Dave & Dave Chartered Accountant as Statutory Auditor of the Company approved by shareholders in 41st Annual General Meeting · 12 Sept 2026
- 41st Annual General Meeting scrutinizers Report · 12 Sept 2026
